期刊文献+

FIB-4及APRI指数对慢性乙型肝炎患者肝纤维化严重程度的评估价值 被引量:10

Value of FIB-4 and APRI index in evaluating the severity of liver fibrosis among patients with chronic hepatitis B
下载PDF
导出
摘要 目的探讨基于4因子的纤维化指数(FIB-4)、天门冬氨酸氨基转移酶(AST)/血小板(PLT)比值(APRI指数)对慢性乙型肝炎(CHB)患者肝纤维化严重程度的评估价值。方法 218例CHB患者为研究对象,根据肝纤维化分期,分为S0~S2组(n=120)及S3~S4组(n=98),比较2组患者的一般资料、实验室指标、FIB-4指数及APRI指数的差异;采用Spearman相关分析对两种指数模型与肝纤维化进行相关分析;绘制受试者工作特征(ROC)曲线评估FIB-4及APRI指数在CHB患者肝纤维化分级大于或等于S2、≥S3及S4时的诊断性能,计算曲线下面积、灵敏度、特异度及最佳截断值,并比较FIB-4指数与APRI指数在评估不同严重程度肝纤维化的效能差异。结果肝纤维化分级大于或等于S2时,FIB-4指数的诊断价值明显优于APRI指数(Z=1.998,P=0.046),而对于肝纤维化分级大于或等于S3(Z=1.177,P=0.239)或S4(Z=0.267,P=0.789)时,FIB-4指数与APRI指数的诊断价值一致。结论 FIB-4指数及APRI指数均能有效地评估CHB患者的肝纤维化严重程度,但对于肝纤维化早期患者,FIB-4指数的评估价值更高。 Objective To explore the value of FIB-4and APRI index on evaluating the severity of liver fibrosis among patients with chronic hepatitis B(CHB).Methods A total of 218 CHB were enrolled in the study.Based on the staging of liver fibrosis,the patients were divided into 2groups as S0-S2group(n=120)and S3-S4group(n=98).Differences in clinical data,laboratory indexes,FIB-4and APRI index were compared between two groups.The correlation between FIB-4index,APRI index and liver fibrosis were analyzed by Spearman correlation test.Receiver operator curve(ROC)test was used to determine the evaluating value of FIB-4index and APRI index for the severity of liver fibrosis.Results To evaluate the staging≥S2of liver fibrosis,the value of FIB-4index was better than APRI index(Z=1.998,P=0.046).And to evaluate the staging≥S3and S4 of liver fibrosis,the value of FIB-4index for evaluating the staging≥S3(Z=1.177,P=0.239)or S4(Z=0.267,P=0.789)was the same as APRI index.Conclusion FIB-4index and APRI index are both effective on evaluating the severity of liver fibrosis among patients with CHB,but the value of FIB-4index is better than APRI index for evaluating early liver fibrosis.
出处 《国际检验医学杂志》 CAS 2017年第15期2076-2078,2081,共4页 International Journal of Laboratory Medicine
关键词 肝纤维化 FIB-4指数 APRI指数 慢性乙型肝炎 liver fibrosis FIB-4index APRI index chronic hepatitis B
  • 相关文献

参考文献2

二级参考文献81

  • 1Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115:209-218 [PMID: 15690074 DOI: 10.1172/JCI200524282].
  • 2Cheng WS, Roberts SK, McCaughan G, Sievert W, Weltman M,Crawford D, Rawlinson W, Marks PS, Thommes J, Rizkalla B,Yoshihara M, Dore GJ. Low virological response and high relapserates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol 2010; 53: 616-623[PMID: 20619475 DOI: 10.1016/j.jhep.2010.04.024].
  • 3McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, GallerGW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER,Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K,Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS.Peginterferon alfa-2b or alfa-2a with ribavirin for treatment ofhepatitis C infection. N Engl J Med 2009; 361: 580-593 [PMID:19625712 DOI: 10.1056/NEJMoa0808010].
  • 4Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A,de Franchis R, Almasio PL, Maisonneuve P. Sustained virologicresponse prevents the development of esophageal varices incompensated, Child-Pugh class A hepatitis C virus-inducedcirrhosis. A 12-year prospective follow-up study. Hepatology 2010;51: 2069-2076 [PMID: 20196120 DOI: 10.1002/hep.23528].
  • 5Stasi C, Piluso A, Arena U, Salomoni E, Montalto P, Monti M,Boldrini B, Corti G, Marra F, Laffi G, Milani S, Zignego AL.Evaluation of the prognostic value of liver stiffness in patients withhepatitis C virus treated with triple or dual antiviral therapy: Aprospective pilot study. World J Gastroenterol 2015; 21: 3013-3019[PMID: 25780300 DOI: 10.3748/wjg.v21.i10.3013].
  • 6European Association for the Study of the Liver. EASL ClinicalPractice Guidelines: management of hepatitis C virus infection.J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023].
  • 7Toccaceli F, Laghi V, Capurso L, Koch M, Sereno S, ScuderiM. Long-term liver histology improvement in patients withchronic hepatitis C and sustained response to interferon. J ViralHepat 2003; 10: 126-133 [PMID: 12614469 DOI: 10.1046/j.1365-2893.2003.00403.x].
  • 8Casado JL, Quereda C, Moreno A, Pez-Els MJ, Mart-BeldaP, Moreno S. Regression of liver fibrosis is progressive aftersustained virological response to HCV therapy in patients withhepatitis C and HIV coinfection. J Viral Hepat 2013; 20: 829-837[PMID: 24304452 DOI: 10.1111/jvh.12108.].
  • 9Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, KaplowitzN, Kiernan TW, Wollman J. Formulation and application of anumerical scoring system for assessing histological activity inasymptomatic chronic active hepatitis. Hepatology 1981; 1:431-435 [PMID: 7308988].
  • 10Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F,Denk H, Desmet V, Korb G, MacSween RN. Histological gradingand staging of chronic hepatitis. J Hepatol 1995; 22: 696-699[PMID: 7560864 DOI: 10.1016/0168-8278(95)80226-6].

共引文献621

同被引文献106

引证文献10

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部